Showing results (281-290 of 7,002) with videos related to

Sort By:
Pageof 701
Lung Cancer (Amsterdam, Netherlands)|June 27, 2003
The role of radiotherapy in treatment of stage I non-small cell lung cancerXueying Qiao, Owe Tullgren, Ingmar Lax, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2003
Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational studySalaheddin M Mahmud, Marie Reilly, Harry Comber
Lung Cancer (Amsterdam, Netherlands)|June 27, 2003
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology GroupDimosthenis-Vasilios Skarlos, Athanassios-Meletios Dimopoulos, Paraskevas Kosmidis, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lungKazuhiro Araki, Genichiro Ishii, Tomoyuki Yokose, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabineJohan Vansteenkiste, Jean Vandebroek, Kris Nackaerts, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2003
Small cell lung cancer survival: 3 years as a minimum for predicting a favorable outcomeTadeusz Lewiński, Maciej Zuławski
Lung Cancer (Amsterdam, Netherlands)|November 18, 2019
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018Maria Lucia Reale, Emmanuele De Luca, Pasquale Lombardi, et al.
Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancerJair Bar, Efrat Ofek, Iris Barshack, et al.
Lung Cancer (Amsterdam, Netherlands)|November 5, 2019
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracyJeffrey C Thompson, Wei-Ting Hwang, Christiana Davis, et al.
Pageof 701